|
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Tea consumption reduces the risk of de novo myelodysplastic syndromes
|
Dec 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.
|
Mar 2012
|
Leuk Res
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Telomerase, hTERT and splice variants in patients with myelodysplastic syndromes
|
Apr 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes
|
Feb 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
|
Mar 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
|
Feb 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry
|
Nov 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
|
Mar 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
